her2
FDA verdict on Enhertu in HER2-low breast cancer due before year-end
Phil Taylor
AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, fda, her2, Oncology
0 Comment
Market Access/ News/ News/ News/ Oncology
AZ, Daiichi challenge Roche with EU okay for earlier use of Enhertu
Phil Taylor
AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, EU, her2, Kadcyla, regulatory approval, Roche, Seagen, Tukysa
0 Comment
Market Access/ News/ News/ News/ Oncology
Byondis cues up US, EU decisions on breast cancer ADC in 2023
Phil Taylor
AstraZeneca, breast cancer, Byondis, Daiichi Sankyo, Enhertu, her2, Kadcyla, Oncology, Roche
0 Comment
Oncology/ Sales and Marketing/ Views & Analysis/ Views & Analysis/ Views and analysis
Redefining the approach to cancer care – a mission to improve patient outcomes
mike.hammerton@pharmaphorum.com
breast cancer, cancer care, company profile, Exact Sciences, her2
0 Comment
Market Access/ News/ News/ News/ Oncology
Enhertu gets breakthrough tag in HER2-low breast cancer
Phil Taylor
antibody-drug conjugate, AstraZeneca, breakthrough Therapy, breast cancer, Daiichi Sankyo, Enhertu, her2, Oncology
0 Comment
Market Access/ News/ News/ News/ Oncology
FDA starts speedy review of Enhertu in lung cancer
Phil Taylor
AstraZeneca, Daiichi Sankyo, Enhertu, her2, Non-small cell lung cancer
0 Comment
Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial
Phil Taylor
AstraZeneca, breast cancer, Daiichi Sankyo, Enhertu, her2
0 Comment
EMA starts review of Enhertu for HER2+ gastric cancer
Phil Taylor
AstraZeneca, Daiichi Sankyo, ema, Enhertu, her2, Oncology, stomach cancer
0 Comment